Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ABVC BioPharma, Inc. (ABVC) has issued an update.
ABVC BioPharma has announced corrections to a previous press release concerning their licensing deals with AiBtl, ForSeeCon, and OncoX. The company clarified that the potential aggregate license fee is $19 million, not $24 million as initially reported. Furthermore, the expected total cash payment from these licensees is $18.7 million, contrary to the previously stated $23.7 million.
For an in-depth examination of ABVC stock, go to TipRanks’ Stock Analysis page.